Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Life Science Alliance|May 17, 2022
DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITFNuria Gutierrez-Prat, Hedwig L Zuberer, Luca Mangano, et al.
Oncotarget|November 4, 2015
5-fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traitsCorti Denise, Paolo Paoli, Maura Calvani, et al.
Journal of Biomedical Nanotechnology|October 30, 2015
Improved Anti-Tumoral Therapeutic Efficacy of 4-Hydroxynonenal Incorporated in Novel Lipid Nanocapsules in 2D and 3D ModelsStefania Pizzimenti, Martina Daga, Eric Ciamporcero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2021
Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF InhibitorJürgen Wichmann, Caroline Rynn, Thomas Friess, et al.
Cancer Research|May 18, 2022
Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain MetastasisEster Bonfill-Teixidor, Raffaella Iurlaro, Cornelia Handl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2026
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid TumorsMaria Vieito, Elisa Fontana, Catherine H Han, et al.
Cancer Research|March 5, 2015
Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancerPiergiorgio Pettazzoni, Andrea Viale, Parantu Shah, et al.
Cancer Research|October 6, 2017
EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome ReprogrammingRemi Adelaiye-Ogala, Justin Budka, Nur P Damayanti, et al.
Cancer Discovery|May 27, 2021
Medium-Chain Acyl-CoA Dehydrogenase Protects Mitochondria from Lipid Peroxidation in GlioblastomaFrancesca Puca, Fei Yu, Caterina Bartolacci, et al.
Pageof 4